The company's average rating is Buy from 7 analysts.
Biolife Solutions advice module can be used to check and cross-verify current investment recommendation provided by
analysts analyzing the company's potential to grow using all of fundamental, technical, data market data available at the time.
The performance of BioLife Solutions in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence BioLife Solutions'
stock prices. When investing in BioLife Solutions, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, BioLife Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as BioLife Solutions carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
How important is BioLife Solutions's Liquidity
BioLife Solutions
financial leverage refers to using borrowed capital as a funding source to finance BioLife Solutions ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. BioLife Solutions financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to BioLife Solutions' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of BioLife Solutions' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between BioLife Solutions's total debt and its cash.
What do experts say about BioLife?
Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
Analysis ConsensusWhat is driving BioLife Solutions Investor Appetite?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biolife Solutions has an asset utilization ratio of 336.79 percent. This connotes that the company is making $3.37 for each dollar of assets. An increasing asset utilization means that Biolife Solutions is more efficient with each dollar of assets it utilizes for everyday operations.
| 2018 | 2019 | 2020 | 2021 (projected) |
Current Assets | 37.56 M | 24.11 M | 27.73 M | 29.92 M | Total Assets | 45.47 M | 92.82 M | 106.74 M | 115.17 M |
Will Biolife Solutions growth be viable after the spike?
Latest variance is at 13.3. Biolife Solutions exhibits very low volatility with skewness of 0.21 and kurtosis of -0.13. However, we advise investors to further study Biolife Solutions technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biolife Solutions' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biolife Solutions' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Bottom Line On Biolife Solutions
While some firms within the medical instruments & supplies industry are still a little expensive, even after the recent corrections, Biolife Solutions may offer a potential longer-term growth to retail investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Biolife nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biolife Solutions.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of BioLife Solutions. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
